These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35373275)

  • 1. Sotorasib Tackles KRASG12C-Mutated Pancreatic Cancer.
    Cancer Discov; 2022 Apr; 12(4):878-879. PubMed ID: 35373275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sotorasib for previously treated colorectal cancers with KRAS
    Fakih MG; Kopetz S; Kuboki Y; Kim TW; Munster PN; Krauss JC; Falchook GS; Han SW; Heinemann V; Muro K; Strickler JH; Hong DS; Denlinger CS; Girotto G; Lee MA; Henary H; Tran Q; Park JK; Ngarmchamnanrith G; Prenen H; Price TJ
    Lancet Oncol; 2022 Jan; 23(1):115-124. PubMed ID: 34919824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers.
    Khan HY; Nagasaka M; Aboukameel A; Alkhalili O; Uddin MH; Bannoura SF; Mzannar Y; Azar I; Beal EW; Tobon ME; Kim SH; Beydoun R; Baloglu E; Senapedis W; El-Rayes BF; Philip PA; Mohammad RM; Shields AF; Al Hallak MN; Azmi AS
    Mol Cancer Ther; 2023 Dec; 22(12):1422-1433. PubMed ID: 37703579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sotorasib as Fourth-Line Treatment in Pancreatic Cancer: A Case Report and Literature Review.
    Onukogu ID; Medawar G; Mangala YO; Rathore R
    R I Med J (2013); 2024 Jul; 107(7):10-13. PubMed ID: 38917307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers.
    Rubinson DA; Tanaka N; Fece de la Cruz F; Kapner KS; Rosenthal MH; Norden BL; Barnes H; Ehnstrom S; Morales-Giron AA; Brais LK; Lemke CT; Aguirre AJ; Corcoran RB
    Cancer Discov; 2024 May; 14(5):727-736. PubMed ID: 38236605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sotorasib in KRAS-Mutated Colorectal Cancer. Reply.
    Fakih MG; Chao J
    N Engl J Med; 2024 Jul; 391(2):187. PubMed ID: 38986068
    [No Abstract]   [Full Text] [Related]  

  • 8. Sotorasib in KRAS-Mutated Colorectal Cancer.
    Fojo T
    N Engl J Med; 2024 Jul; 391(2):186-187. PubMed ID: 38986067
    [No Abstract]   [Full Text] [Related]  

  • 9. A saturation mutagenesis screen uncovers resistant and sensitizing secondary
    Feng S; Callow MG; Fortin JP; Khan Z; Bray D; Costa M; Shi Z; Wang W; Evangelista M
    Proc Natl Acad Sci U S A; 2022 May; 119(18):e2120512119. PubMed ID: 35471904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonclinical Safety Profile of Sotorasib, a KRAS
    Ishida K; Werner JA; Davies R; Fan F; Thomas B; Wahlstrom J; Lipford JR; Monticello T
    Int J Toxicol; 2021 Oct; 40(5):427-441. PubMed ID: 34137282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sotorasib in KRAS
    Olivier T; Prasad V
    Lancet; 2024 Jan; 403(10422):145. PubMed ID: 38218611
    [No Abstract]   [Full Text] [Related]  

  • 12. Sotorasib in KRAS
    Paz-Ares L; Mehta B; Wang Y; Obiozor C; Waterhouse D; de Langen AJ
    Lancet; 2024 Jan; 403(10422):145-146. PubMed ID: 38218612
    [No Abstract]   [Full Text] [Related]  

  • 13. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
    Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
    Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sotorasib: First Approval.
    Blair HA
    Drugs; 2021 Sep; 81(13):1573-1579. PubMed ID: 34357500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling.
    Fedele C; Li S; Teng KW; Foster CJR; Peng D; Ran H; Mita P; Geer MJ; Hattori T; Koide A; Wang Y; Tang KH; Leinwand J; Wang W; Diskin B; Deng J; Chen T; Dolgalev I; Ozerdem U; Miller G; Koide S; Wong KK; Neel BG
    J Exp Med; 2021 Jan; 218(1):. PubMed ID: 33045063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modifying Trial Design May Be Key to Full Sotorasib Approval.
    Cancer Discov; 2023 Dec; 13(12):OF4. PubMed ID: 37830786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS-targeted therapies in advanced solid cancers: drug the undruggable?
    Saleh K; Kordahi M; Felefly T; Kourie HR; Khalife N
    Pharmacogenomics; 2021 Jul; 22(10):587-590. PubMed ID: 34148378
    [No Abstract]   [Full Text] [Related]  

  • 18. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
    Sun H; Zhang B; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sotorasib effective in KRAS-mutant NSCLC.
    Sidaway P
    Nat Rev Clin Oncol; 2021 Aug; 18(8):470. PubMed ID: 34140669
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful Use of Sotorasib in a Patient With End-Stage Renal Disease on Dialysis With Metastatic Lung Adenocarcinoma: A Case Report.
    Sproat MR; Hofherr ML; Devarakonda S
    Clin Lung Cancer; 2022 Sep; 23(6):e339-e341. PubMed ID: 35643747
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.